DexCom, Inc. vs Microchip Technology Inc. — how do they compare? DexCom, Inc. trades at $90.3 (market cap $33.79B), while Microchip Technology Inc. trades at $80.64 (market cap $43.99B). The key difference: Microchip Technology Inc. is the larger of the two by market cap, and Microchip Technology Inc. pays a 2.25% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MCHP | |
|---|---|---|
Market Cap | $33.79B | $43.99B |
Sector | Health | Technology |
52-Week High | $89.53 | $102.97 |
52-Week Low | $54.84 | $49.02 |
Enterprise Value | $33.24B | $49.12B |
Dividend Yield | — | 2.25% |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Microchip Technology (MCHP) trades at $80.45, down 1.15% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats, including Q1 2026 EPS of $0.57 versus $0.505 expected (Zacks Investment Research, 2026-08-07), highlight robust demand recovery and data center growth. The company maintains solid profitability with a 60.19% gross margin but faces high valuation multiples like a P/E of 119.15.
The outlook is positive driven by AI and data center expansion, with a consensus price target of $104.00 (MarketBeat, 2026-08-07). Risks include elevated debt levels and sensitivity to semiconductor cycles. Upside potential exists if execution continues to exceed expectations amid broadening demand.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →